Today: 21 May 2026
Browse Category

NYSE:ENLAY 30 June 2025

Stock Market Today

  • Astral Limited FYE Results: Analysts Forecast 16% Revenue Growth in 2027
    May 20, 2026, 9:05 PM EDT. Shares of Astral Limited (NSE:ASTRAL) dropped 6.5% after its full-year results revealed earnings per share (EPS) of ₹19.97, missing forecasts by 2.2%. Revenue of ₹66 billion met expectations. Looking ahead, 27 analysts project 2027 revenues of ₹76.3 billion, a 16% rise, and EPS growth of 36% to ₹27.10. Previous estimates were slightly lower, signaling confidence unchanged by recent results. Price targets range from ₹1,378 to ₹2,150, with a consensus target of ₹1,742. Expected revenue growth aligns roughly with the industry average of 14%, accelerating from Astral's historical 11% annual growth. Analysts remain cautiously optimistic on Astral's medium-term outlook.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop